- Home
- COOK vs CHRS Comparison
COOK vs CHRS Comparison
Compare COOK & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COOK
- CHRS
- Stock Information
- Founded
- COOK 1985
- CHRS 2010
- Country
- COOK United States
- CHRS United States
- Employees
- COOK N/A
- CHRS N/A
- Industry
- COOK Wholesale Distributors
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COOK Consumer Discretionary
- CHRS Health Care
- Exchange
- COOK Nasdaq
- CHRS Nasdaq
- Market Cap
- COOK 184.8M
- CHRS 194.1M
- IPO Year
- COOK 2021
- CHRS 2014
- Fundamental
- Price
- COOK $1.04
- CHRS $1.67
- Analyst Decision
- COOK Hold
- CHRS Strong Buy
- Analyst Count
- COOK 7
- CHRS 4
- Target Price
- COOK $2.07
- CHRS $4.51
- AVG Volume (30 Days)
- COOK 289.9K
- CHRS 1.1M
- Earning Date
- COOK 11-05-2025
- CHRS 11-07-2025
- Dividend Yield
- COOK N/A
- CHRS N/A
- EPS Growth
- COOK N/A
- CHRS N/A
- EPS
- COOK N/A
- CHRS 1.55
- Revenue
- COOK $579,453,000.00
- CHRS $272,209,000.00
- Revenue This Year
- COOK N/A
- CHRS N/A
- Revenue Next Year
- COOK $2.21
- CHRS $109.48
- P/E Ratio
- COOK N/A
- CHRS $1.07
- Revenue Growth
- COOK N/A
- CHRS 52.33
- 52 Week Low
- COOK $0.98
- CHRS $0.66
- 52 Week High
- COOK $3.59
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- COOK 39.29
- CHRS 53.48
- Support Level
- COOK $1.02
- CHRS $1.64
- Resistance Level
- COOK $1.15
- CHRS $1.82
- Average True Range (ATR)
- COOK 0.06
- CHRS 0.10
- MACD
- COOK 0.00
- CHRS -0.03
- Stochastic Oscillator
- COOK 28.11
- CHRS 13.46
About COOK Traeger Inc.
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.